Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial
about
Progress in adjuvant chemotherapy for breast cancer: an overviewAdjuvant chemotherapy for early female breast cancer: a systematic review of the evidence for the 2014 Cancer Care Ontario systemic therapy guidelinePresentation and management of docetaxel-related adverse effects in patients with breast cancerBenefit risk assessment and update on the use of docetaxel in the management of breast cancer.Optimal systemic therapy for early breast cancer in women: a clinical practice guidelineEffectiveness of an Adjuvant Chemotherapy Regimen for Early-Stage Breast Cancer: A Systematic Review and Network Meta-analysis.Randomised phase III trial of FEC120 vs EC-docetaxel in patients with high-risk node-positive primary breast cancer: final survival analysis of the ADEBAR study.Adjuvant taxane-based chemotherapy for early stage breast cancer: a real-world comparison of chemotherapy regimens in Ontario.Randomized controlled trial of late-course concurrent versus sequential chemoradiotherapy after mastectomy and axillary surgery in locally advanced breast cancer.The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 triaA Phase IV Clinical Trial of Patients with Solid Tumors Receiving Lenograstim as Primary Prophylaxis for Chemotherapy-Induced Neutropenia, in a Docetaxel-Based Regimen
P2860
Q26798078-FAF1C109-CFF5-4C42-989B-E46826DB82BDQ26853619-21633305-C1BD-4FAC-9249-E76DDA3A12DAQ33698286-D286133D-E605-4D6C-BB04-FFAE94BBFFDCQ34379034-D898E0FC-A650-4C1A-B796-9495F661BDBBQ35239634-004D49AD-AF04-47EA-AD63-8D120B5BC8E7Q35786472-B7D4AB9E-BAFB-47B4-A0CF-9A5370292DB4Q37174738-616EFBB7-E7DA-4050-B837-C3B98942CC00Q41706289-06BCC659-94B1-4F5E-955B-E0F8DC21125EQ47107032-5FE24982-C8B4-4A62-A50D-578FC0A8D91AQ55096327-F1768E12-EB35-4D34-B7AD-D46E0FD78919Q59050832-D68E082D-C3E1-4D9B-99B5-0DBB982701E9
P2860
Extended benefit from sequential administration of docetaxel after standard fluorouracil, epirubicin, and cyclophosphamide regimen for node-positive breast cancer: the 8-year follow-up results of the UNICANCER-PACS01 trial
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Extended benefit from sequenti ...... of the UNICANCER-PACS01 trial
@ast
Extended benefit from sequenti ...... of the UNICANCER-PACS01 trial
@en
type
label
Extended benefit from sequenti ...... of the UNICANCER-PACS01 trial
@ast
Extended benefit from sequenti ...... of the UNICANCER-PACS01 trial
@en
prefLabel
Extended benefit from sequenti ...... of the UNICANCER-PACS01 trial
@ast
Extended benefit from sequenti ...... of the UNICANCER-PACS01 trial
@en
P2093
P2860
P1433
P1476
Extended benefit from sequenti ...... of the UNICANCER-PACS01 trial
@en
P2093
Anne-Laure Martin
Bernard Asselain
Bruno Audhuy
Bruno Coudert
Christelle Lévy
Corinne Veyret
Daniel Serin
Frédérique Pénault-Llorca
Gilles Piot
Gilles Romieu
P2860
P304
P356
10.1634/THEONCOLOGIST.2011-0442
P577
2012-05-18T00:00:00Z